Litcius/Paper detail

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Jan Philipp Bewersdorf, Rory M. Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E. Roe, Jonathan M. Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F. Madanat, Joshua F. Zeidner, Jessica K. Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A. Podoltsev, Stephanie Halene, Richard F. Little, Richard Piekarz, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan

2023Annals of Hematology22 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineMyelodysplastic syndromesHypomethylating agentOncologyPembrolizumabMyeloid leukemiaLenalidomideDecitabineCancerBone marrowMultiple myelomaImmunotherapyDNA methylationGeneBiochemistryChemistryGene expressionAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchImmune cells in cancer
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents | Litcius